Analystreport

Trillium Therapeutics Inc (NASDAQ: TRIL) had its price target lowered by analysts at HC Wainwright from $10.00 to $4.00. They now have a "buy" rating on the stock.

Trillium Therapeutics Inc. - Common Shares  (TRIL) 
Last trillium therapeutics inc. - common shares earnings: 5/13 07:00 am Check Earnings Report